Publication alert: randomized trial of CDT vs. anticoagulation for intermediate high risk PE. Catheter-Directed Thrombolysis vs Anticoagulation in Patients With Acute Intermediate-High–risk Pulmonary... ja.ma/3F8NSIc via JAMA Cardiology part of JAMA Network

Join us Thursday & Friday online for #Thrombosis & #Thromboembolism , our legacy two-day course covering updates in the field of thrombosis--plus earn up to 14.75 #CE credits from Oakstone Publishing! Learn more: hubs.la/Q01qt-Fs0. #MedEd

Protecting our patients during a global shortage of thrombolytics: proud to coauthor this call to action in The Lancet with Saskia Middeldorp Grégoire Le Gal and Professor Beverley Hunt OBE 🇺🇦 OBE #WTDay22 thelancet.com/journals/lance…

#Subgroup analyses in #RCTs have✅&🚫. In #VTE , Nerea Báez Gutiérrez studied 28 RCTs, ~half claimed subgroup effects: Only 2 solid. Thrombosis Research Editorial by Tobias Tritschler Parham Sadeghipour & I suggests Dos & Don’ts w subgroup analyses. tinyurl.com/yeypkmc6 & tinyurl.com/3m3pzd5h

Excited to present primary results of the large IMPROVE-DD cluster RCT for medically-ill for LBS Nov 7 8-9am #AHA22 and AHA Science North American Thrombosis Forum Anticoagulation Forum PERT Consortium Thrombosis UK Thrombosis Canada CanVECTOR Network European Society of Cardiology European Thrombosis & Haemostasis Alliance (ETHA) ISTH #thrombosis

I may not have received an interview invitation yet, but my first authored paper will receive simultaneous publications in JACC Journals and AHA Science #AHA22 in two weeks 🤩

#Match2023
jacc.org/events/confere…

A modified reperfusion protocol for intermediate-risk #pulmonaryembolism seemed to work without causing excessive bleeding in the small randomized CANARY trial, reported Behnood Bikdeli of Brigham and Women's Hospital & Harvard Medical School.

bit.ly/3gr1PH1 #CardioTwitter MedPage Today Nicole Lou

Behnood Bikdeli Azita Talasaz Parham Sadeghipour Liverpool Centre for Cardiovascular Science North American Thrombosis Forum Read article here 🖱️ thieme-connect.com/products/ejour…

Thanks so much Brigham and Women’s Research Brigham and Women's Hospital for covering our JAMA Cardiology #RCT of #Catheter directed #Thrombolysis vs #Anticoagulation 💉 in pts w #PulmonaryEmbolism
bwhclinicalandresearchnews.org/2022/10/01/wha…

RCT of 94 pts w intermediate-high–risk PE, cCDT compared w anticoagulation monotherapy didn't decrease the proportion of pts with a 3-mo right ventricle to left ventricle ratio of >0.9 but was associated with improvement in other imaging parameters. ja.ma/3MQDN4E

Congrats to this effort led by Behnood Bikdeli! The 2nd ever RCT of anticoag vs catheter directed lysis for acute PE.

Looking forward to much more randomized data to come in this space!

Thanks so much Todd Neale TCTMD Cardiovascular Research Foundation for covering the results of our #CANARY 🐤 #trial of cCDT vs anticoagulation in intermediate-risk PE. Parham Sadeghipour

We’ve relied on 2020 data for #COVID19 associated #thrombsosis . Little known RE effects of new #viral variants, #vaccines 💉, and #antiviral therapies until lately. Azita Talasaz et al nicely illustrates this until 02/2022. Data emerging now for epi, and for treatment effect of💊.

ICYMI: It's October's What's Hot In Clots, our #digest on latest trials & news in the world of #thrombosis with Behnood Bikdeli! This edition covers #aspirin vs #warfarin based on data from MAQI2, #PACIFICstroke trial results, & more. Read: hubs.la/Q01pGrS_0. #WHIC

#COVID19 Associated Pulmonary Embolism: Review of the Pathophysiology, Epidemiology, Prevention, Diagnosis, and Treatment LHCH LJMUHealth Institute of Life Course and Medical Sciences Liverpool Health Partners thieme-connect.de/products/ejour…

#COVID -19 associated #PE shares some pathophys & clinical features with nonCOVID PE, but some are different:⬆️Incidence & ⬆️in ♂️ & obesity c/w nonCOVID PE. Management may need distinct considerations. Wonderful effort by Luis Ortega Paz Brigham and Women’s Research tinyurl.com/yckfzwdv

A2: Hospital-associated #thrombosis can occur in patients up to 90 days following discharge making it critical that we educate patients about the sign, symptoms and risk factors of #bloodclots . #ClotChat #WTDay22